City
Epaper

Hyderabad based BioGenex develops Direct RT-PCR Kit which detects all variants of Covid-19 Double Quick

By ANI | Published: January 13, 2022 12:10 PM

BioGenex Life Sciences Pvt Ltd. has developed a RT-PCR kit for Covid-19 diagnosis, which detects COVID 19 caused by SARS COV 2 variants including "OMICRON" plus other variants.

Open in App

BioGenex Life Sciences Pvt Ltd. has developed a RT-PCR kit for Covid-19 diagnosis, which detects COVID 19 caused by SARS COV 2 variants including "OMICRON" plus other variants.

The NIB, Noida, an ICMR designated lab, examined the performance of this kit and found that it performed with 100% accuracy which means no false negatives or positives, which will significantly control the pandemic through accurate diagnosis. The kit detects Omicron variant in half the time than standard RT-PCR test.

The TRIPLEX COVID-19 RT-PCR Direct is a real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 directly from the upper respiratory swab, nasopharyngeal or oropharyngeal swabs, collected in preservative media, (VTM/UTM), pH 7.2-7.4 to provide the molecular diagnostic basis for infected patients.

This test analyses samples in VTM directly without the need for RNA extraction step. It helps scientists for rapid tracking of disease prevalence and aid in treatment insight (e.g. hospital beds, oxygen ventilators and expensive medications) for healthcare systems in making appropriate measures to combat COVID-19.

There are many challenges associated with ramping up testing capacity, due to supply chain delays and shortage of extraction reagents, this situation call-up for alternative protocols to ensure the continuity of testing in laboratories. Due to increased demand for SARS-CoV-2 variants screenings, an alternative protocol with similar sensitivity is required, said Dr. Krishan Kalra, CEO BioGenex.

He further added, "Sustained surveillance is essential for public health. Our latest tests reduce the cost of testing and turnaround time for the result. As we learn from the pandemic, we are partnering with concerned organizations to understand and strengthen our diagnostic portfolio to develop-deliver reliable and sustainable diagnostic solutions in the future."

For more info on COVID 19 products please visit: . IngenuityD is a special spinoff from BioGenex which caters to COVID 19 diagnostic market.

This story is provided by BusinessWire India.will not be responsible in any way for the content of this article. (ANI/BusinessWire India)

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Biogenex life sciences pvt ltd.NibKrishan kalra
Open in App

Related Stories

NationalCan't confirm XE COVID variant in Maharashtra, awaiting report results from Centre, says health minister Rajesh Tope

PoliticsTN Narcotic bureau ties up with animators for campaign against drug abuse

Health81% samples have UK Covid variant: Punjab CM

Business Realted Stories

BusinessGujarat to resume air ambulance service following scheduled maintenance

BusinessIndian-descent Nikesh Arora 2nd highest paid CEO in US, says report

BusinessWidespread 5G spectrum availability to add $27 billion to India's GDP: GSMA

BusinessIndiGo flight delayed after crew spots overbooked passenger standing at the back

BusinessIndia is on the cusp of a long-awaited economic takeoff: RBI